clinical trials

News

ESMO: GSK, iTeos bring some optimism back to TIGIT

GSK and iTeos anti-TIGIT antibody belrestotug showed efficacy in a phase 2 trial in PD-L1-positive non-small cell lung cancer (NSCLC), providing some much-needed positive news for the belea

News

ESMO: Enhertu shows its worth in brain metastases

Women with HER2-positive breast cancer can be treated with AstraZeneca and Daiichi Sankyo's Enhertu, regardless of whether their cancer has spread to the brain, according to a new study.

News

Herpes simplex virus (HSV-2) capsid visualisation

GSK drops HSV jab, leaving rival mRNA shots in pole position

GSK has abandoned its clinical-stage vaccine for herpes simplex virus (HSV) after a disappointing phase 1/2 trial, ceding the ground to mRNA shots in development at Moderna and BioNTech.

News

Dupixent delivers in two skin disease trials

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications f

News

Study backs role of Novo Nordisk obesity drug in children

A clinical trial has backed the safety and efficacy of one of Novo Nordisk's weight-loss medicines in children as young as six, showing a significant drop in body mass index (BMI).

News

Viridian takes aim at Amgen's Tepezza with veligrotug data

Thyroid eye disease (TED) therapy Tepezza – the biggest asset in Amgen's $26 billion takeover of Horizon last year – could soon face competition from a drug in the same class from Viridian

ESMO: GSK, iTeos bring some optimism back to TIGIT

ESMO: Enhertu shows its worth in brain metastases

GSK drops HSV jab, leaving rival mRNA shots in pole position

Dupixent delivers in two skin disease trials

Study backs role of Novo Nordisk obesity drug in children

Viridian takes aim at Amgen's Tepezza with veligrotug data

Gilead strikes again, penning $5bn deal to buy Tubulis

Using AI-driven synthetic personas to take your insights fur...

clinical trials

Editor's Picks